Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

In drug-naïve subjects with type 2 diabetes ... The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

Diabetes is very common in people living in post-acute and long-term environments, affecting 25% to 34% of these individuals.

The legislature’s Education and Culture Committee yesterday said that it would establish an interministerial anti-vaping ...

This combination medication contains pioglitazone, a thiazolidinedione agent and alogliptin, a DPP-4 inhibitor. It comes as a tablet, which contains 25 mg alogliptin and 15 mg pioglitazone to take ...

This combination medication contains alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin, a biguanide. •Caution should be exercised in patients with history of pancreatitis ...

Nine separate alleged drug dealers will now have their legal proceedings combined in a new twist in a bust involving more ...

He said the prosecution had not presented sufficient evidence to sustain the charge under Section 39B (1) (a) of the Dangerous Drug Act 1952. Amirul faced the death penalty if convicted. He pleaded ...